骨髓间充质干细胞对缺血性心脏病的治疗作用及机制探讨  

Transplantation of bone marrow derived-mesenchymal stem cells in treatment of ischemic heart diseases and its mechanism

作　　者：石雪峰[1,2,3] 王华[2] 格日力[1] 

机构地区：[1]青海大学医学院高原医学研究中心,西宁810001 [2]军事医学科学院放射与辐射医学研究所,北京100850 [3]青海省人民医院呼吸科,西宁810007

出　　处：《军事医学》2016年第5期441-444,F0003,共5页Military Medical Sciences

基　　金：国家973计划资助项目(2012CB518205);国家自然科学基金资助项目(81573086;31571231)

摘　　要：骨髓间充质干细胞(BM-MSC)除了具有自我复制、多向分化潜能、低免疫原性外,还具有可归巢至损伤局部,向心肌细胞及脉管系统分化,通过旁分泌作用分泌多种因子及动员内在的心肌干细胞等生物学特性,因此成为缺血性疾病治疗中细胞及基因治疗的理想工程细胞。但是BM-MSC应用于缺血性心脏病(IHD)治疗仍有诸多问题亟待解决,相信随着研究的深入,人类必将利用间充质干细胞治疗这种新的策略攻克IHD治疗中的一系列难题。Apart from the self-renew multi-differentiation capacity and immunosuppressive property,bone marrowderived mesenchymal stem cells（ BM-MSCs） can home to the injury site,differentiate into cardiomyocytes and promote angiogenesis,secrete bioactive levels of soluble factors（ growth factors and cytokines） by paracrine secretion and recruit endogenous cardiac stem cells. These characteristics have made BM-MSCs ideal cells for gene therapy. There are also many problems with the treatment of ischemic heart diseases（ IHD） via stem cells. However,with the development of combined treatments for both cardiac regeneration and the repair of damaged myocardial tissue,these problems will be solved sooner or later.

关 键 词：骨髓间充质干细胞 缺血性心脏病 旁分泌 归巢 

分 类 号：R541[医药卫生—心血管疾病]